Prevention of cardiotoxicity among survivors of childhood cancer
| Autor: | Kelley K. Hutchins, Vivian I. Franco, Steven E. Lipshultz, Hani Siddeek |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Pharmacology
Cardiotoxicity medicine.medical_specialty Pediatrics business.industry Childhood cancer Cancer 030204 cardiovascular system & hematology medicine.disease Surgery 03 medical and health sciences 0302 clinical medicine 030220 oncology & carcinogenesis medicine Pharmacology (medical) Dexrazoxane business medicine.drug |
| Zdroj: | British Journal of Clinical Pharmacology. 83:455-465 |
| ISSN: | 0306-5251 1476-5381 |
| Popis: | Linked Articles This article is part of a joint Themed section with the British Journal of Pharmacology on Cardiotoxicity. The rest of the Themed section will appear in a future issue of BJP and will be available at http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1476-5381 The number of survivors of childhood cancers has increased exponentially over the past few decades. However, these survivors are also at substantially increased long-term risk of morbidity and mortality, especially from treatment-related cardiotoxicity. Preventing these risks is now a priority when treating children and adolescents with cancer. Dexrazoxane reduces the risk of anthracycline-induced cardiotoxicity among adults and children with cancer without reducing its antineoplastic effects or event-free survival. Thus, it should be strongly considered as a part of therapy for children and adolescents treated with anthracyclines. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text